KRON News and Press, Kronos Bio Inc. From 11/04/21

SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Charles Lin, Ph.D., Senior Vice President, Biology, will participate in the Emerging Tr...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present preclinical data in a poster at the AACR-NCI-EORTC Virtual Internationa...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Marni Kottle as senior vice president of Corporate Communications and Inv...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwrig...

Announced FDA clearance of Investigational New Drug application (IND) for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML) Unveiled SYK portfolio strategy and highlighted momentum of CDK9 inhibitor and discovery programs at virtual R&D Day ...

Company intends to develop LANRA as a once-daily chronic treatment for genetically-defined AML patients Two Phase 1/2 clinical trials of LANRA are planned, with first trial to initiate in Q4 2021 SAN MATEO, Calif. and CAMBRIDGE, Mass., July 27, 2021 (GLOBE NEWSWIRE) -- Krono...

Kronos IPO'd in October. Its lead asset Entospletinib is targeting a subset of AML patients. The company is well funded, with $398mn in cash. For further details see: Kronos: Recent IPO Developing Novel Oncology Therapies

Unveils development strategy for lanraplenib (LANRA), which will expand addressable patient population for SYK inhibitor portfolio in acute myeloid leukemia (AML); plans to initiate two Phase 1/2 trials in late 2021 and early 2022 On track to initiate registrational Phase 3 tria...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...

Kronos Bio  (KRON): Q1 GAAP EPS of -$0.48 misses by $0.05.As of March 31, 2021, cash, cash equivalents and investments totaled $440.6 million.Press Release For further details see: Kronos Bio  EPS misses by $0.05